Nolvaxyl 20 mg

Nolvaxyl 20 mg contains tamoxifen citrate, which is FDA-approved for the treatment of metastatic breast cancer in women and men, adjuvant treatment of breast cancer, treatment of ductal carcinoma in situ (DCIS), and reduction of breast cancer incidence in women at high risk. In non-medical bodybuilding contexts, tamoxifen is commonly referenced in PCT protocols after anabolic steroid cycles to help restore endogenous testosterone production, though such use falls outside approved indications.

In FDA-approved medical use, tamoxifen for metastatic breast cancer is dosed at 20 to 40 mg daily, given as a single dose or in divided doses . For adjuvant treatment, the recommended dose is 20 mg daily for 5 to 10 years. In non-medical PCT protocols, tamoxifen is commonly referenced at 20 mg per day for 4 to 6 weeks, sometimes starting at 40 mg for the first 2 weeks.

Tamoxifen is itself commonly used as a PCT agent. It does not suppress the HPG axis and is used to stimulate endogenous testosterone production after suppressive anabolic steroid cycles. Standard non-medical PCT protocols reference tamoxifen at 20 mg per day for 4 to 6 weeks. The efficacy of PCT is still unproven, and medical guidance is advised.

Tamoxifen (brand name Nolvadex) competitively binds to estrogen receptors, blocking the effects of endogenous estrogens in target tissues . In the hypothalamus and pituitary, this blockade reduces estrogen-mediated negative feedback on the HPG axis, leading to increased GnRH, LH, and FSH secretion. The increase in LH enhances testosterone production in the Leydig cells . In clinical research, tamoxifen 20 mg daily for 6 weeks significantly increased LH (211%), FSH (215%), and total testosterone (157%) levels in men.

Tamoxifen is extensively metabolized in the liver, with steady-state concentrations achieved in approximately 4 weeks. In clinical research, significant increases in LH, FSH, and testosterone levels were observed after 6 weeks of daily 20 mg dosing. For gynecomastia, clinical studies have used treatment courses of 2 to 12 months.

There is no single PCT agent that is universally best. Human data show tamoxifen raises testosterone comparably or better than clomiphene at lower milligram doses with a more favorable side-effect profile. Tamoxifen is commonly referenced in PCT protocols, as is Clomixyl 50 mg. The appropriate choice depends on individual factors and medical guidance.

Both tamoxifen and clomiphene are selective estrogen receptor modulators (SERMs) commonly referenced in PCT protocols. Human data show tamoxifen produces a comparable or larger gonadotropin response at lower doses than clomiphene. Clomiphene carries a higher rate of visual disturbances and mood changes attributed to its estrogen-agonist activity. Tamoxifen is available as Nolvaxyl 20 mg while clomiphene is available as Clomixyl 50 mg.

Tamoxifen is a SERM that blocks estrogen receptors, while anastrozole is an aromatase inhibitor that reduces estrogen production by blocking the aromatase enzyme. Tamoxifen is commonly referenced for PCT, while anastrozole is sometimes referenced for managing estrogenic side effects during cycles. Anastrozole is available as Arimixyl 1 mg.

A 20 mg tablet represents the standard FDA-approved daily dose for adjuvant breast cancer treatment, DCIS, and breast cancer risk reduction. In clinical research for gynecomastia, tamoxifen has been studied at 20-40 mg/day. In non-medical PCT protocols, 20 mg per day is the standard dose.

Nolvaxyl 20 mg is labeled at 20 mg of tamoxifen citrate per tablet. It is supplied in packs of 30 or 100 tablets.

Yes, tamoxifen has been studied for the treatment of gynecomastia. Clinical research in boys with pubertal gynecomastia found that tamoxifen at 20-40 mg/day for 2-12 months resulted in complete resolution in most cases. A retrospective study of 38 patients with persistent pubertal gynecomastia found that tamoxifen treatment resulted in a mean reduction in breast nodule diameter of 2.1 cm, with improvement seen in 86% of patients. In a comparison study, complete resolution was recorded in 78.2% of patients treated with tamoxifen (20 mg/d) for idiopathic gynecomastia.

Laboratory testing information for Nolvaxyl 20 mg is not currently available in this product listing. Kalpa Pharmaceuticals products are manufactured under pharmaceutical-grade conditions, but independent lab reports are not published for this specific product at this time.